163 related articles for article (PubMed ID: 24913509)
1. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.
Poon ML; Fox PS; Samuels BI; O'Brien S; Jabbour E; Hsu Y; Gulbis A; Korbling M; Champlin R; Abruzzo LV; Bassett RL; Khouri IF
Leuk Lymphoma; 2015 Mar; 56(3):711-5. PubMed ID: 24913509
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
3. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.
Salihoglu A; Ozbalak M; Keskin D; Tecimer T; Soysal T; Ferhanoglu B
Transplant Proc; 2013 Sep; 45(7):2845-8. PubMed ID: 23747187
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
Thompson PA; Stingo F; Keating MJ; Wierda WG; O'Brien SM; Estrov Z; Ledesma C; Rezvani K; Qazilbash M; Shah N; Parmar S; Popat U; Anderlini P; Yago N; Ciurea SO; Kebriaei P; Champlin R; Shpall EJ; Hosing CM
Br J Haematol; 2017 May; 177(4):567-577. PubMed ID: 28295181
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
Dreger P; Döhner H; Ritgen M; Böttcher S; Busch R; Dietrich S; Bunjes D; Cohen S; Schubert J; Hegenbart U; Beelen D; Zeis M; Stadler M; Hasenkamp J; Uharek L; Scheid C; Humpe A; Zenz T; Winkler D; Hallek M; Kneba M; Schmitz N; Stilgenbauer S;
Blood; 2010 Oct; 116(14):2438-47. PubMed ID: 20595516
[TBL] [Abstract][Full Text] [Related]
6. Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation.
Farina L; Barretta F; Scarfò L; Bruno B; Patriarca F; Frustaci AM; Coscia M; Salvetti C; Quaresmini G; Fanin R; Onida F; Magagnoli M; Zallio F; Vallisa D; Reda G; Ferrario A; Corradini P; Montillo M
Biol Blood Marrow Transplant; 2020 Oct; 26(10):e256-e262. PubMed ID: 32653626
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
8. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Chavez JC; Kharfan-Dabaja MA; Kim J; Yue B; Dalia S; Pinilla-Ibarz J; Anasetti C; Locke FL
Leuk Res; 2014 Oct; 38(10):1165-72. PubMed ID: 24889511
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of stem cell transplantation in chronic lymphocytic leukemia.
Dreger P;
Hematol Oncol Clin North Am; 2013 Apr; 27(2):355-69. PubMed ID: 23561478
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Poiré X; Labopin M; Maertens J; Yakoub-Agha I; Blaise D; Ifrah N; Socié G; Gedde-Dhal T; Schaap N; Cornelissen JJ; Vigouroux S; Sanz J; Michaux L; Esteve J; Mohty M; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):20. PubMed ID: 28100265
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
12. Allotransplantation for chronic lymphocytic leukemia.
Dreger P
Hematology Am Soc Hematol Educ Program; 2009; ():602-9. PubMed ID: 20008245
[TBL] [Abstract][Full Text] [Related]
13. What is the best frontline therapy for patients with CLL and 17p deletion?
Badoux XC; Keating MJ; Wierda WG
Curr Hematol Malig Rep; 2011 Mar; 6(1):36-46. PubMed ID: 21153774
[TBL] [Abstract][Full Text] [Related]
14. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
Pavletic ZS; Arrowsmith ER; Bierman PJ; Goodman SA; Vose JM; Tarantolo SR; Stein RS; Bociek G; Greer JP; Wu CD; Kollath JP; Weisenburger DD; Kessinger A; Wolff SN; Armitage JO; Bishop MR
Bone Marrow Transplant; 2000 Apr; 25(7):717-22. PubMed ID: 10745256
[TBL] [Abstract][Full Text] [Related]
15. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.
Delgado J; Espinet B; Oliveira AC; Abrisqueta P; de la Serna J; Collado R; Loscertales J; Lopez M; Hernandez-Rivas JA; Ferra C; Ramirez A; Roncero JM; Lopez C; Aventin A; Puiggros A; Abella E; Carbonell F; Costa D; Carrio A; Gonzalez M; ;
Br J Haematol; 2012 Apr; 157(1):67-74. PubMed ID: 22224845
[TBL] [Abstract][Full Text] [Related]
17. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
19. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
Tam CS; Shanafelt TD; Wierda WG; Abruzzo LV; Van Dyke DL; O'Brien S; Ferrajoli A; Lerner SA; Lynn A; Kay NE; Keating MJ
Blood; 2009 Jul; 114(5):957-64. PubMed ID: 19414856
[TBL] [Abstract][Full Text] [Related]
20. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]